Versatility of Aminoglycosides and Prospects for Their Future

By S. Vakulenko, S. Mobashery. Clinical Microbiology Reviews, 2003

622 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Aminoglycosides: An Overview. (2016, background): “Aminoglycosides are also inactive against most Burkholderia spp. and Stenotrophomonas spp. as well as Streptococcus spp. and Enterococcus spp. (Brogden et al. 1976; Vakulenko and Mobashery 2003; Brooke 2012; Podnecky et al. 2015).”
How antibiotics kill bacteria: from targets to networks (2010, background): “, and with cellular energetics, ribosome binding and protein mistranslation following treatment with inhibitors of protein synthesi”
Acquired Antibiotic Resistance Genes: An Overview (2011, methodology): “Ie PHT 906 AY743255 131..1036 Enterococcus aph(3′)-Ia PHT 816 J01839 1162..1977 Escherichia, Klebsiella, Pseudomonas, Salmonella aph(3′)-Ib PHT 816 M20305 779..1594 Escherichia aph(3′)-Ic PHT 816 X625115 410..1225 Acinetobacter, Citrobacter, Escherichia, Klebsiella, Salmo- nella, Serratia, Yersinia ”
How to manage Pseudomonas aeruginosa infections (2018, background): “The AME mostly identified in P. aeruginosa belongs to the AAC and ANT families [39,40].”
Aminoglycoside Modifying Enzymes (2010, background): “N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript Vakulenko and Mobashery, 2003) and mediates resistance to gentamicin, tobramycin, dibekacin, sisomicin, and kanamycin.”